Sandoz Looks To Biosimilars As It Reprioritizes In The US
US Sandoz President Carol Lynch Talks Changing Portfolio
Sandoz US president Carol Lynch talked to Scrip about its changing US portfolio, which will emphasize biosimilars, as the Novartis unit is poised to divest most of its US generics portfolio to Aurobindo.
